Evidence map›Paper›PMID 41279785›Full record

ArticlebioRxiv : the preprint server for biology2025

Optimization of velocity receptor transduction in CAR T cells.

Xinyun Jiang, Vasco Queiroga, Eban A Hanna, Denis Wirtz

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Xinyun JiangInstitute for Nanobiotechnology, The Johns Hopkins University, Baltimore, 21218, Maryland, USA.
Vasco QueirogaInstitute for Nanobiotechnology, The Johns Hopkins University, Baltimore, 21218, Maryland, USA.
Eban A HannaInstitute for Nanobiotechnology, The Johns Hopkins University, Baltimore, 21218, Maryland, USA.
Denis WirtzInstitute for Nanobiotechnology, The Johns Hopkins University, Baltimore, 21218, Maryland, USA.

Funding

Tech Core 2U54CA268083 · NCI · JOHNS HOPKINS UNIVERSITY · PI Andrew Josef Ewald · 2022 to 2026
$10.2M
Engineering self-propelled tumor-infiltrating CAR T cells using synthetic velocity receptorsR01CA300052 · NCI · JOHNS HOPKINS UNIVERSITY · PI Denis Wirtz · 2025 to 2026
$1.3M
Three-dimensional maps of senescence in the human pancreasUG3CA275681 · NCI · JOHNS HOPKINS UNIVERSITY · PI WU, PEI-HSUN · 2022 to 2023
$1.1M
NCI NIH HHS R01 CA300052NCI NIH HHS U54 CA268083NCI NIH HHS UG3 CA275681
6 · The paper itself

Abstract

Limited infiltration capacity significantly limits the effectiveness of chimeric antigen receptor (CAR) T cells for solid tumors. We have recently developed a large family of highly modular synthetic cytokine receptors termed velocity receptors (VRs), capable of binding key inflammatory cytokines, such as IL5, IL8, and TNFα, which drive CAR T cells into an elevated motility state. These new CAR T cells sense and amplify these autocrine secreted cytokines, thereby maintaining a self-propelled, high migratory state, facilitating penetration into dense tumor cores. In this study, we systematically evaluated key factors influencing VR transduction in order to improve their stable integration and expression. We established a dual-fluorescence reporter system to allow simultaneous monitoring of both VR and CAR constructs, and while evaluating modifications to the vector construct and generating standardized infectious unit (IFU) curves under various conditions. Our results demonstrate that the attempt to reduce overall lentiviral vector size by eliminating non coding sections upstream of the central polypurine tract (cPPT) do not yield better transduction efficiency, though it is unclear if the effect is due to viral production or integration impairment. We also observed a log-linear relationship between viral dose and transduction efficiency for a subset of VRs previously tested in various mouse models of human cancer, with VR5αIL8 and VR5αTNFα VRs consistently outperforming VR5αIL5 and V5 (full length native IL5 receptor). Overall, these findings establish an optimized and reproducible framework that offers valuable guidance for the future development and functional study of VR-CAR T cells in cellular therapies for solid tumors.

Indexed as

CAR T cellscPPTIFU curveslentiviral transductionvelocity receptors

Identifiers

PMID41279785
PMCPMC12632405

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.